News Related to Simple Endoscopic Score for Crohn's Disease

Related coverage linked through entity extraction aliases.

Upadacitinib and Risankizumab Show Comparable Remission in Crohn’s Disease After Anti-TNF Failure

Jul 21, 2026

A retrospective study found comparable corticosteroid-free remission with upadacitinib and risankizumab in anti-TNF-exposed Crohn’s patients. Upadacitinib showed higher endoscopic remission at week 52 but more adverse events. Both JAK and IL-23 inhibitors are shaping the growing IBD treatment market.

Real-world study reports upadacitinib outcomes in anti-TNF-refractory Crohn’s disease

May 05, 2026

A retrospective real-world study of 108 Chinese patients with anti-TNF-refractory Crohn’s disease found upadacitinib clinical remission rates of 55.1% at week 12 and 52.5% at week 24.